Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 13/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19079433 | 0.82 | SMYD3 (0.58) | SMYD3PSMB8PSMB9PSMB5 | |
| SCHEMBL19079182 | 0.79 | SMYD3 (0.56) | SMYD3RAB9ANPC1TSHRPSMB8 | |
| SCHEMBL19079439 | 0.78 | SMYD3 (0.62) | SMYD3 | |
| SCHEMBL23507683 | 0.77 | SMYD3 (0.47) | SMYD3RAB9ANPC1TSHRPSMB8 | |
| SCHEMBL19079458 | 0.77 | SMYD3 (0.58) | SMYD3 | |
| SCHEMBL19079174 | 0.77 | SMYD3 (0.56) | SMYD3RAB9ANPC1TSHRPSMB8 | |
| SCHEMBL22518513 | 0.76 | RAB9A (0.63) | SMYD3RAB9ANPC1TSHRSTAT1 | |
| SCHEMBL2618802 | 0.76 | RAB9A (0.64) | SMYD3RAB9ANPC1TSHRSTAT1 | |
| SCHEMBL19079455 | 0.75 | SMYD3 (0.58) | SMYD3 | |
| SCHEMBL19079454 | 0.75 | SMYD3 (0.52) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885RAB9A 210/4885NPC1 2214/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885RAB9A 210/4885NPC1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.